401 related articles for article (PubMed ID: 30124154)
1. The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia.
Oesterle A; Liao JK
Curr Vasc Pharmacol; 2019; 17(3):222-232. PubMed ID: 30124154
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic Effects of Statins on the Cardiovascular System.
Oesterle A; Laufs U; Liao JK
Circ Res; 2017 Jan; 120(1):229-243. PubMed ID: 28057795
[TBL] [Abstract][Full Text] [Related]
3. Effect of statins on atherosclerotic plaque.
Almeida SO; Budoff M
Trends Cardiovasc Med; 2019 Nov; 29(8):451-455. PubMed ID: 30642643
[TBL] [Abstract][Full Text] [Related]
4. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
5. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
6. The Use of Statins in the Treatment and Prevention of Atrial Fibrillation.
Groves D; Mihos CG; Larrauri-Reyes M; Santana O
Cardiol Rev; 2016; 24(5):224-9. PubMed ID: 26401903
[TBL] [Abstract][Full Text] [Related]
7. The evolving role of statins in the management of atherosclerosis.
Vaughan CJ; Gotto AM; Basson CT
J Am Coll Cardiol; 2000 Jan; 35(1):1-10. PubMed ID: 10636252
[TBL] [Abstract][Full Text] [Related]
8. Understanding the molecular mechanisms of statin pleiotropic effects.
German CA; Liao JK
Arch Toxicol; 2023 Jun; 97(6):1529-1545. PubMed ID: 37084080
[TBL] [Abstract][Full Text] [Related]
9. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.
Liao JK
Am J Cardiol; 2005 Sep; 96(5A):24F-33F. PubMed ID: 16126020
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular mechanisms of statins: an update on pleiotropic effects.
Satoh M; Takahashi Y; Tabuchi T; Minami Y; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M
Clin Sci (Lond); 2015 Jul; 129(2):93-105. PubMed ID: 25927679
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Marzilli M
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728
[TBL] [Abstract][Full Text] [Related]
14. Prevention of stroke and dementia with statins: Effects beyond lipid lowering.
Vaughan CJ
Am J Cardiol; 2003 Feb; 91(4A):23B-29B. PubMed ID: 12615295
[TBL] [Abstract][Full Text] [Related]
15. Lipids: a personal view of the past decade.
Katsiki N; Mikhailidis DP
Hormones (Athens); 2018 Dec; 17(4):461-478. PubMed ID: 30229482
[TBL] [Abstract][Full Text] [Related]
16. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
Takemoto M; Liao JK
Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1712-9. PubMed ID: 11701455
[TBL] [Abstract][Full Text] [Related]
18. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe.
Fazio S
Atheroscler Suppl; 2015 Feb; 17():23-6. PubMed ID: 25659873
[TBL] [Abstract][Full Text] [Related]
19. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
Adhyaru BB; Jacobson TA
Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance.
Biasucci LM; Biasillo G; Stefanelli A
Clin Chem Lab Med; 2010 Dec; 48(12):1685-91. PubMed ID: 20868311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
